NCT06628908ClinicalTrials.gov
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
باختصار
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
المرحلة 3مطلوب 1,100 مشارك76 موقعاًدولة واحدة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT06628908فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل شهرين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 7 days after the recorded start)First posted 2024-10-08; recorded start 2024-10-01
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 92 other studies in this databaseCounted from the lead sponsor named in the record (Vertex Pharmaceuticals Incorporated)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 76 sites
- Data monitoring committee0/7
Data monitoring committee not stated in the record
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study: 1,100 participants (target), run at 76 sites.
How this score is built
- Enrolment30/40
1,100 participants (target)
- Site count22/25
76 sites
- Country count0/15
Single country
- Planned duration8/10
Planned over about 32 months
- Sponsor scale7/10
Vertex Pharmaceuticals Incorporated has led 90 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
الحالات
- Diabetic Peripheral Neuropathic Pain
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – 80 Years |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 3 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 1,100 مشارك |
الجهة الراعية والمتعاونون
- Vertex Pharmaceuticals Incorporated الجهة الراعية
الأذرع والتدخلات
- Suzetrigine (SUZ)EXPERIMENTAL
Participants will be randomized to receive SUZ.
- PregabalinACTIVE_COMPARATOR
Participants will be randomized to receive Pregabalin.
- PlaceboPLACEBO_COMPARATOR
Participants will be randomized to receive placebo matched to SUZ and Pregabalin.
التدخلات
- دواء Placebo (matched to Pregabalin)
Placebo matched to Pregabalin for oral administration.
- دواء Placebo (matched to SUZ)
Placebo matched to SUZ for oral administration.
- دواء Pregabalin
Capsules for oral administration.
- دواء Suzetrigine
Tablets for oral administration.
مقاييس النتائج
مقياس النتيجة الأولي
Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo
الإطار الزمني From Baseline up to Week 12
مقياس النتيجة الثانوي
Change From Baseline in the Medical Outcomes Study 36-item Short-form Health Status (SF 36v2) Physical Component Summary (PCS) Score at Week 12 Compared to Placebo (pooled with data from Study VX24-548-111)
الإطار الزمني From Baseline up to Week 12
مقياس النتيجة الثانوي
Change From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS at Week 12 Compared to Pregabalin
الإطار الزمني From Baseline up to Week 12
التواريخ
| تاريخ البدء | 1 أكتوبر 2024 (فعلي) |
|---|---|
| الإتمام الأولي | 31 مايو 2027 (تقديري) |
| الإتمام | 31 مايو 2027 (تقديري) |
| أول نشر | 8 أكتوبر 2024 (فعلي) |
| آخر تحديث | 15 يونيو 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | يونيو 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
59 موقعاً قيد التجنيد
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Albany Medical College | Albany | New York | مكتمل |
| Velocity Clinical Research - Albuquerque | Albuquerque | New Mexico | قيد التجنيد |
| Synexus Clinical Research- Anderson | Anderson | South Carolina | مكتمل |
| Pinnacle Research Group, LLC | Anniston | Alabama | قيد التجنيد |
| Velocity Clinical Research - Baton Rouge | Baton Rouge | Louisiana | قيد التجنيد |
| Velocity Clinical Research - Cleveland | Beachwood | Ohio | قيد التجنيد |
| Northwest Clinical Research Center (NWCRC) | Bellevue | Washington | قيد التجنيد |
| Synexus Clinical Research - Birmingham | Birmingham | Alabama | مكتمل |
| Mass General Brigham - Brigham and Women's Hospital - Main Campus | Boston | Massachusetts | قيد التجنيد |
| Swift Clinical OpCo, Inc | Brooklyn | New York | قيد التجنيد |
| Clinical Trials of South Carolina - Berkeley - Charleston | Charleston | South Carolina | قيد التجنيد |
| M3 Wake Research - Charleston | Charleston | South Carolina | قيد التجنيد |
| Feinberg School of Medicine - Anesthesiology | Chicago | Illinois | قيد التجنيد |
| Synexus Clinical Research - Cincinnati | Cincinnati | Ohio | مكتمل |
| Tandem Clinical Research- Covington | Covington | Louisiana | قيد التجنيد |
| Synexus Clinical Research - Dallas (DFW) (DRS) | Dallas | Texas | مكتمل |
| Zenos Clinical Research | Dallas | Texas | قيد التجنيد |
| AMR Daphne, AL | Daphne | Alabama | مكتمل |
| META Medical Research Institute | Dayton | Ohio | قيد التجنيد |
| Accel Research - Deland | DeLand | Florida | قيد التجنيد |
| Accel Research - Decatur | Decatur | Georgia | قيد التجنيد |
| AMR-Miami | Doral | Florida | قيد التجنيد |
| Velocity Clinical Research - Providence | East Greenwich | Rhode Island | قيد التجنيد |
| Velocity Clinical Research - Syracuse | East Syracuse | New York | قيد التجنيد |
| Velocity Clinical Research - Denver | Englewood | Colorado | قيد التجنيد |
| Synexus Clinical Research - Evansville | Evansville | Indiana | مكتمل |
| Healthcare Research Network - Flossmoor IL | Flossmoor | Illinois | قيد التجنيد |
| AMR Fort Myers (The Clinical Study Center) | Fort Myers | Florida | قيد التجنيد |
| Neuro-Pain Medical Center | Fresno | California | قيد التجنيد |
| Velocity Clinical Research - Grants Pass | Grants Pass | Oregon | مكتمل |
| Velocity Clinical Research - Hallandale Beach | Hallandale | Florida | قيد التجنيد |
| Healthcare Research Network - Hazelwood MO | Hazelwood | Missouri | قيد التجنيد |
| CNS Healthcare - Jacksonville | Jacksonville | Florida | قيد التجنيد |
| AMR Kansas City | Kansas City | Missouri | قيد التجنيد |
| Accel Research - St. Petersburg-Largo | Largo | Florida | قيد التجنيد |
| Synexus Clinical Research - Las Vegas | Las Vegas | Nevada | مكتمل |
| AMR Lexington | Lexington | Kentucky | قيد التجنيد |
| Long Beach Research Institute | Long Beach | California | قيد التجنيد |
| Angel City Research, Inc | Los Angeles | California | قيد التجنيد |
| Accel Research - Maitland | Maitland | Florida | مكتمل |
| HRI - Hassman Research Institute | Marlton | New Jersey | مكتمل |
| Velocity Clinical Research - Medford | Medford | Oregon | قيد التجنيد |
| Suburban Research Associates - Media | Media | Pennsylvania | قيد التجنيد |
| Velocity Clinical Research - Boise | Meridian | Idaho | قيد التجنيد |
| Suncoast Research Associates - Miami | Miami | Florida | قيد التجنيد |
| 3Sync Research - Miami Lakes | Miami Lakes | Florida | قيد التجنيد |
| West Clinical Research | Morehead City | North Carolina | قيد التجنيد |
| AMR Nashville, TN | Nashville | Tennessee | مكتمل |
| Suncoast Clinical Research - New Port Richey | New Port Richey | Florida | قيد التجنيد |
| Columbia Presbyterian - The Neurological Institute of New York | New York | New York | قيد التجنيد |
يُدرَج 26 موقعاً إضافياً في سجل السجل.
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
لم تُسجَّل أي تغييرات منذ أن أدرجنا هذا السجل لأول مرة.
يُسجَّل تغيير في كل مرة تحدّث فيها الجهة الراعية سجل السجل. تظهر هنا الحالة والتواريخ والتجنيد والمواقع كلما تغيّرت.